Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Conference Call for Q2FY24 - Audio Recording01-11-2023
01-11-2023
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 202301-11-2023
Mankind Pharma Share Price Live blog for 01 Nov 2023
Mankind Pharma stock price went down today, 01 Nov 2023, by -0.61 %. The stock closed at 1753.3 per share. The stock is currently trading at 1742.6 per share. Investors should monitor Mankind Pharma stock price closely in the coming days and weeks to see how it reacts to the news.01-11-2023
Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Mankind Pharma Ltd.
Pharmaceuticals company Mankind Pharma announced Q2FY24 & H1FY24 results: Q2FY24: Revenue from Operations at Rs 2,708 crore, up by 12% YoY Domestic revenue at Rs 2,529 crore, up by 7% YoY Export revenue at Rs 179 crore, up by 159% YoY EBITDA at Rs 686 crore, up by 15% YoY with a margin of 25% PAT at Rs 511 crore, up by 21% YoY with a margin of 19% Cash flow from operations of Rs 481 crore Diluted EPS of Rs 12.5, up by 19% YoY (FV Re 1) H1FY24: Revenue from Operations at Rs 5,287 crore, up by 15% YoY Domestic revenue at Rs 4,948 crore, up by 10% YoY Export revenue at Rs 339 crore, up by 182% YoY EBITDA at Rs 1,346 crore, up by 28% YoY with a margin of 25% PAT at Rs 1,005 crore, up by 40% YoY with a margin of 19% Diluted EPS of Rs 24.6, up by 39% YoY (FV Re 1) CAPEX of Rs 225 crore Net cash balance of Rs 2,159 crore as on September 30, 2023 Rajeev Juneja, Vice Chairman & Managing Director, said, “ We continue to report steady performance with Revenue/ EBITDA and PAT growing by 12% / 15% and 21% YoY respectively. While the Pharma segment has grown at par with IPM (vs outperformance earlier) – due to delayed acute season, we expect to outperform IPM given strong chronic growth and uptick in season. Focus on increasing our chronic share led to the outperformance of 1.4x versus IPM Chronic growth in H1FY24. The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in the future.” Result PDF31-10-2023
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Financial Results of Q2FY23-2431-10-2023
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release on Financial Results for the quarter and half year ended on September 30, 202331-10-2023
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Announcement under Regulation 30 (LODR) - Amalgamation / Merger31-10-2023
Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. October 31, 2023
Outcome of Board Meeting held today i.e. October 31, 202331-10-2023
Mankind Pharma Ltd - 543904 - Outcome Of Board Meeting Held Today I.E. October 31, 2023
Outcome of Board Meeting held today i.e. October 31, 202331-10-2023
Mankind Pharma Ltd - 543904 - Intimation For Receipt Of Request For Reclassification Of Shareholding From 'Promoter And Promoter Group' Category To 'Public' Category Pursuant To The Provisions Of Regulation 31A Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')
Intimation for receipt of request for reclassification of shareholding from ''Promoter and Promoter Group'' category to ''Public'' Category pursuant to the provisions of Regulation 31A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations'').28-10-2023